D. Kohn

发表

Immune response to green fluorescent protein: implications for gene therapy

D. Kohn, R. Stripecke, M. Villacres, 1999, Gene Therapy.

Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.

W. Anderson, M. Clerici, K. Weinberg, 1999, Human gene therapy.

Gene transfer into human umbilical cord blood-derived CD34+ cells by particle-mediated gene transfer

D. Kohn, G. Nabel, U. Ranga, 1998, Gene Therapy.

Immunotherapy against murine leukemia

H. Koeffler, D. Kohn, S. Vos, 1998, Leukemia.

Expression of human Wiskott–Aldrich syndrome protein in patients’ cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins

S. Tsuboi, U. Francke, J. Derry, 2000, Gene Therapy.

Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study.

C. Dunbar, D. Kohn, 1996, Human gene therapy.

Retrovirus-mediated transfer of the human α- L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts

D. Kohn, X. Yu, E. Kakkis, 1997, Gene Therapy.

The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice

D. Skelton, N. Satake, D. Kohn, 2001, Gene Therapy.

Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.

W. Anderson, D. Kohn, C. Raffel, 1994, Human gene therapy.

Z. Ram, W. Anderson, E. Oldfield, 1996, Journal of insurance medicine.